CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 153 enrolled
Drug / intervention
Ramosetrondrug
Likely dose
Ramosetron 0.3mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01102491
NCT01102491Phase 4Completed

The Effect of Multimodal Anti-emetic Protocol on Postoperative Nausea and Vomiting After Total Knee Arthroplasty

Seoul National University Hospital·interventional·Posted Apr 13, 2010·Updated Jun 8, 2012

In Brief

A Phase 4 clinical trial evaluating Ramosetron for Osteoarthritis, Knee. Completed, enrolled 153 participants across 1 site.

Detailed Summary

The purposes of this study are to document the antiemetic efficacy of multimodal antiemetic protocol in patient after Total Knee Arthroplasty using regional anesthesia, midazolam \& propofol, hydration \& oxygen supplement, preemptive \& multimodal contemporary pain management and to determine whether Ramosetron prophylaxis would provide additional antiemetic effect on this protocol. We hypothesized that the incidence of Postoperative nausea and vomiting during multimodal antiemetic protocol would be lower than Apfel's expected postoperative nausea and vomiting incidence. It was also hypothesized that Ramosetron prophylaxis would provide additional antiemetic effect.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesSouth Korea
Collaborators--

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 13, 2010
Enrollment StartSep 1, 2009
Primary CompletionFeb 1, 2010
Study CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 16.2 years ago

Interventions

Ramosetrondrug

ramosetron intravenous injection, 0.3mg, 1 time/day for 2 days